Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow AMLX by emailGet an email when AMLX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AMLX, unsubscribe in one click. Privacy
📣 What AMLX Says Is Next
by the end of 2026 · “Our NDA submission readiness is well underway, and we continue to advance our preparations for a potential commercial launch of avexitide in 2027, if approved.” Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026.”
Company press release, Aug 18, 2026 · SEC filing
by year-end · “Amylyx plans to submit an NDA for avexitide with the FDA by year-end; avexitide has Breakthrough Therapy and Orphan Drug Designations by the FDA”
Company press release, Aug 18, 2026 · SEC filing
in 2027 · “If approved, commercial launch of avexitide is anticipated in 2027.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full AMLX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMLX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.